Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
吲哚胺2,3-双加氧酶1 (IDO1) 抑制剂navoximod (GDC-0919) 治疗复发性晚期实体瘤患者的Ia期研究
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1186/s40425-018-0351-9
Nayak-Kapoor, Asha; Hao, Zhonglin; Sadek, Ramses; Dobbins, Robin; Marshall, Lisa; Vahanian, Nicholas N; Jay Ramsey, W; Kennedy, Eugene; Mautino, Mario R; Link, Charles J; Lin, Ray S; Royer-Joo, Stephanie; Liang, Xiaorong; Salphati, Laurent; Morrissey, Kari M; Mahrus, Sami; McCall, Bruce; Pirzkall, Andrea; Munn, David H; Janik, John E; Khleif, Samir N